Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.30 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899747 | 0.75 | FFAR3 (0.32) | FFAR3 | |
| SCHEMBL27646262 | 0.74 | FFAR3 (0.33) | FFAR3LMNABLMSMN1; SMN2 | |
| SCHEMBL5899634 | 0.72 | FFAR3 (0.30) | FFAR3 | |
| SCHEMBL5899695 | 0.72 | GRM2 (0.34) | FFAR3 | |
| SCHEMBL12799910 | 0.71 | FFAR3 (0.33) | FFAR3 | |
| SCHEMBL11352697 | 0.71 | FFAR3 (0.33) | FFAR3 | |
| SCHEMBL27646261 | 0.71 | ALDH1A1 (0.35) | FFAR3USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL5899738 | 0.70 | — | — | |
| SCHEMBL5643708 | 0.70 | USP2 (0.41) | FFAR3USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL5899689 | 0.70 | USP2 (0.36) | FFAR3USP2ALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1764634-A | Cyclopropyl beta-amino acid derivatives | WARNER LAMBERT CO (US) | 2006-04-26 | — | — | CN | claimed |
| US-7030267-B2 | Cycloproply β-amino acid derivatives | WARNER-LAMBERT COMPANY, LLC (US) | 2006-04-18 | — | — | US | claimed |
| EP-1592661-A2 | CYCLOPROPYL BETA-AMINO ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-11-09 | — | — | EP | claimed |
| WO-2004065361-A2 | CYCLOPROPYL BETA-AMINO ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | claimed |
| US-20040147608-A1 | Cyclopropyl beta-amino acid derivatives | SCHWARZ JACOB BRADLEY (US) | 2004-07-29 | — | — | US | claimed |
| CN-1764634-A | Cyclopropyl beta-amino acid derivatives | WARNER LAMBERT CO (US) | 2006-04-26 | — | — | CN | disclosed |
| US-7030267-B2 | Cycloproply β-amino acid derivatives | WARNER-LAMBERT COMPANY, LLC (US) | 2006-04-18 | — | — | US | disclosed |
| US-20040147608-A1 | Cyclopropyl beta-amino acid derivatives | SCHWARZ JACOB BRADLEY (US) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147608-A1 | Cyclopropyl beta-amino acid derivatives | CACNA1S, CACNA1D, CACNA1B | FFAR3 655/4885USP2 3632/4885ALDH1A1 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.